alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
No. 930.

#### Scherck, Richter Co. *v.*Dysart et al., Members of the Central Properties First Mortgage Bondholders' Committee, et al.

March 16, 1942.

*Mr. Lyle M. Allen*for petitioner. *Mr. Thomas S. McPheeters*for respondents.

Petition for writ of certiorari to the Circuit Court of Appeals for the Eighth Circuit denied.
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration
 By Notice dated September 8, 2008, and published in the 
                    **Federal Register**
                     on September 15, 2008 (73 FR 53280), Chattem Chemicals Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug
Schedule4-Methoxyamphetamine (7411)
IDihydromorphine (9145)
IDifenoxin (9168)
IAmphetamine (1100)
IIMethamphetamine (1105)
IILisdexamfetamine (1205)
IIMethylphenidate (1724)
IIPentobarbital (2270)
IICodeine (9050)
IIDihydrocodeine (9120)
IIOxycodone (9143)
IIHydromorphone (9150)
IIHydrocodone (9193)
IIMeperidine (9230)
II( print page 4055)Dextropropoxyphene, bulk (non-dosage forms) (9273)
IIMorphine (9300)
IIOripavine (9330)
IIThebaine (9333)
IIOxymorphone (9652)
IINoroxymorphone (9668)
IIAlfentanil (9737)
IIReminfentanil (9739)
IISufentanil (9740)
IIFentanyl (9801)
II
 The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Chattem Chemicals Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Chattem Chemicals Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: January 14, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


[FR Doc. E9-1199 Filed 1-21-09; 8:45 am] BILLING CODE 4410-09-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Energy

###### Federal Energy Regulatory Commission

          - [Docket No. OA08-14-006]

Take notice that on October 14, 2009, Midwest Independent Transmission System Operator, Inc., tendered for filing an information filing regarding operational penalties.

Any person desiring to intervene or to protest this filing must file in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211, 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a notice of intervention or motion to intervene, as appropriate. Such notices, motions, or protests must be filed on or before the comment date. Anyone filing a motion to intervene or protest must serve a copy of that document on the Applicant and all the parties in this proceeding.

                    The Commission encourages electronic submission of protests and interventions in lieu of paper using the “eFiling” link at                     *http://www.ferc.gov*. Persons unable to file electronically should submit an original and 14 copies of the protest or intervention to the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426.                

                    This filing is accessible online at                     *http://www.ferc.gov*, using the “eLibrary” link and is available for review in the Commission's Public Reference Room in Washington, DC. There is an “eSubscription” link on the Web site that enables subscribers to receive e-mail notification when a document is added to a subscribed docket(s). For assistance with any FERC Online service, please e-mail                     *FERCOnlineSupport@ferc.gov*, or call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.                

*Comment Date:*                     5 p.m. Eastern Time on November 4, 2009.                

Kimberly D. Bose,

Secretary.

[FR Doc. E9-25613 Filed 10-23-09; 8:45 am]

BILLING CODE 6717-01-P
#### Keith Renard HARRIS, Petitioner-Appellant, v. DIRECTOR, VIRGINIA DEPARTMENT OF CORRECTIONS, Respondent-Appellee. Keith Renard Harris, Petitioner-Appellant, v. Director, Virginia Department of Corrections, Respondent-Appellee. Keith Renard Harris, Petitioner-Appellant, v. Director of Virginia Department of Corrections, Respondent-Appellee.

Nos. 06-6688, 06-6689, 06-6692.

United States Court of Appeals, Fourth Circuit.

Submitted: Sept. 29, 2006.

Decided: Nov. 15, 2006.

Keith Renard Harris, Appellant Pro Se. Robert Francis McDonnell, Attorney General, Michael Thomas Judge, Office of the Attorney General of Virginia, Richmond, Virginia, for Appellee.

Before MICHAEL, MOTZ, and KING, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).

PER CURIAM.

Keith Renard Harris seeks to appeal the district court’s orders denying relief on his 28 U.S.C. § 2254 (2000) petitions. The orders are not appealable unless a circuit justice or judge issues a certificate of appealability. 28 U.S.C. § 2253(c)(1) (2000). A certificate of appealability will not issue absent “a substantial showing of the denial of a constitutional right.” 28 U.S.C. § 2253(e)(2) (2000). A prisoner satisfies this standard by demonstrating that reasonable jurists would find that any assessment of the constitutional claims by the district court is debatable or wrong and that any dispositive procedural ruling by the district court is likewise debatable. *Miller-El v. Cockrell,*537 U.S. 322, 336-38, 123 S.Ct. 1029, 154 L.Ed.2d 931 (2003); *Slack v. McDaniel,*529 U.S. 473, 484, 120 S.Ct. 1595, 146 L.Ed.2d 542 (2000); *Rose v. Lee,*252 F.3d 676, 683-84 (4th Cir.2001). We have independently reviewed the records and conclude that Harris has not made the requisite showing. Accordingly, we deny certificates of appealability and dismiss the appeals. We also deny Harris’ motion to expand request for certificate of appealability. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*DISMISSED*
Unassociated Document


    Surfect
      Holdings, Inc.

    1800
      West
      Broadway Road

    Tempe,
      Arizona 85252

     

    December
      3, 2007

     

    Reference
      is made to the Engagement Letter, dated November 28, 2007 (“Letter”), between
      Surfect Holdings, Inc. (the “Company) and Westminster Securities Corp. Section 2
      of the Letter shall be deleted in its entirety and replaced with the following
      in lieu thereof:

     

    “2. Warrant
      Consideration:
      At each
      closing of a Financing, the Company shall issue to Westminster or its designees
      warrants to purchase 7% (or
      with
      respect to securities placed through other brokerage firms, 9% of the securities
      placed through such firms) of the total common stock issued and issuable from
      the Financing (including common stock underlying warrants and convertible
      securities),
      exercisable at the lowest of the purchase, conversion, or exercise price per
      share of any securities issued to investors in such Financing. Such warrants
      shall have registration, antidilution, and cashless exercise rights under the
      same terms as any warrants issued to investors in such Financing, and otherwise
      under customary, mutually agreeable terms.”

     

    Except
      as
      modified and amended herein, the Letter shall remain in full force and effect
      in
      accordance with its terms.

     

    
      	 	 	 	 Sincerely,
              
	 	 	 	 
	 	 	 	 Surfect
              Holdings,
	 	 	 	 
	 	 	 	
              By:

            	/s/
              Steven Anderson
	 	 	 	 	
              Steven
                Anderson, President and CEO

            
	 	 	 	 	 
	 Acknowledged
              and Agreed:	 	 	 
	 	 	 	 
	 WESTMINSTER
              SECURITIES CORP.	 	 	 
	 	 	 	 
	
              By:

            	/s/
              John P. O’Shea	 	 	 
	
               

            	
              
                Name:
                  John P. O’Shea

                Title: Chairman
                  and CEO
**Exhibit 23.1****CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**We haveissued our report dated December 7, 2007, accompanying theconsolidated balance sheet of Zoltek Companies Inc. as of September30, 2007, and the related consolidated statements of operations,shareholders’ equity, and cash flows for the year then ended andSchedule II, and our report on internal control over financialreporting included in the Annual Report on Form 10-K for the yearended September 30, 2007, filed with the Securities and ExchangeCommission. We hereby consent to the incorporation by reference of ourreports in previously filed registration statements onForm S-3 (File No. 333-143996) and on form S-8 (File No.’s33-83160, 333-145113, 333-145114 and 33-06565).   /s/ Grant Thornton LLP Chicago, Illinois  December 7, 2007
EXHIBIT 13.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
      AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the filing of the Annual Report of LanOptics Ltd. (the
"Company") on Form 20-F for the period ending December 31, 2004 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Dror Israel, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of
2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.




                                /S/ DROR ISRAEL*
                                ------------------
                                DROR ISRAEL
                                CHIEF FINANCIAL OFFICER

                                MARCH 31, 2005


* The originally executed copy of this Certification will be maintained at the
Company's offices and will be made available for inspection upon request.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby  given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and  552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential  trade secrets or commercial property such as patentable material, and personal information concerning individuals  associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of  personal privacy.

*Name of Committee:*                         Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee.                    

*Date:*                         October 29-30, 2009.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814.                    

*Contact Person:*                         Helen Lin, PhD, Scientific Review Officer, NIH/NIAMS/RB, 6701 Democracy Blvd., Suite 800, Plaza One, Bethesda, MD 20817, 301-594-4952,                          *linh1@mail.nih.gov*.                    

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the  review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases  Research, National Institutes of Health, HHS)

      ( print page 54588)    
Dated: October 14, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-25410 Filed 10-21-09; 8:45 am]

BILLING CODE 4140-01-P
#### In the Matter of Jasiah T.-V.S.J. Heart Share Human Services of New York, Respondent; Joshua W. Appellant.

[976 NYS2d 412]

In a proceeding pursuant to Social Services Law § 384-b to terminate parental rights, the father appeals from an order of

*718the Family Court, Kings County (Olshansky, J.), dated September 24, 2012, which, after a hearing, granted the petitioner’s motion for a determination that the father’s consent to the adoption of the subject child was not required pursuant to Domestic Relations Law § 111 (1) (d).

Ordered that the order is affirmed, without costs or disbursements.

The Family Court’s determination that the father’s consent to the adoption of the subject child was not required is supported by clear and convincing evidence *(see Matter of Julian J.C. [Juan C.],*96 AD3d 937 [2012]). The father, an out-of-wedlock father whose child had been placed with an adoptive parent more than six months after his birth, failed to meet his burden of establishing that he maintained substantial and continuous or repeated contact with the child through the payment of support and either regular visitation or other communication with him *(see*Domestic Relations Law § 111 [1] [d]; *Matter of Robert O. v Russell K.,*80 NY2d 254, 264 [1992]; *Matter of Andrew Peter H.T.,*64 NY2d 1090, 1091 [1985]; *Matter of Michael A.B. [Richard A.B.],*98 AD3d 579, 579-580 [2012]; *Matter of Julian J.C. [Juan C.],*96 AD3d 937 [2012]; *Matter of Charle Chiedu E. [Chiedu E.],*87 AD3d 1140, 1141 [2011]). Mastro, J.E, Lott, Austin and Roman, JJ., concur.
# Clinical Trials

Learn about clinical trials and get connected to resources to gather information on these medical studies

##                     Information for Patients            

### What Is a Clinical Trial?

                    Clinical trials are medical research studies in which people participate as volunteers.            

### Clinical Trials at NIAMS

                    Find NIAMS studies seeking patients to better understand conditions and find effective treatment.            

### NIH Clinical Trials

                    Search the database of clinical trials being conducted at the NIH.            

### What Is ClinicalTrials.gov?

                    Find out more about the database of public and private clinical trials available around the globe.            

### NIH Clinical Research Trials and You

                    Learn what clinical trials are, who participates, and your protections as a volunteer.            

### Clinical Trials in the Spotlight

                    Learn about actively recruiting research studies.            

##                     Information for Principal Investigators            

### Conducting Clinical Trials

                    The NIAMS clinical trials program supports the spectrum of such studies.            

### Clinical Trial Policies, Guidelines, and Templates

                    Understand the NIAMS, NIH, and other federal policies and guidelines.            

### Registering With ClinicalTrials.gov

                    Follow the steps to register your clinical trial with ClinicalTrials.gov.            

#### ClinicalTrials.gov

ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.

Visit ClinicalTrials.gov

April 2024

Back to Top
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2682 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2682

      To extend the temporary suspension of duty on Pyrimethanil.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            November 2, 2009

   Mr. Burr introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
      To extend the temporary suspension of duty on Pyrimethanil.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. PYRIMETHANIL.

    (a) In General.--Heading 9902.10.36 of the Harmonized Tariff 
Schedule of the United States (relating to Pyrimethanil) is amended by 
striking ``12/31/2009'' and inserting ``12/31/2011''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
EXHIBIT 32.2



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,



AS ADOPTED PURSUANT TO



SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report on Form 10-Q of Bio-Imaging Technologies, Inc. (the Company) for the quarter ended March 31, 2005 as
filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Ted I. Kaminer, Senior Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350,
that:



(1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and



(2) The information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bio-Imaging Technologies, Inc.



|                    |  |                                                                                                               
|------------------- |  | --------------------------------------------------------------------------------------------------------------
|                    |  | /s/ Ted I. Kaminer*                                                                                           
|Dated: May 16, 2005 |  | Ted I. Kaminer, Senior Vice President and Chief
Financial Officer (Principal Financial and Accounting Officer)

---

|* | A signed original of this written statement required by Section 906 has been provided to us and will be retained by us and furnished to the Securities and Exchange Commission or its
staff upon request.
|- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------